Bone marrow transplantation for myelodysplastic and myeloproliferative syndromes

M. R. O'Donnell, A. P. Nademanee, D. S. Snyder, G. M. Schmidt, P. M. Parker, Philip Jay Bierman, J. L. Fahey, A. S. Stein, R. A. Krance, A. D. Stock, S. J. Forman, K. G. Blume

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Twenty patients (age range, 4 to 48 years; median age, 36 years) with de novo or drug-induced myelodysplastic syndromes or myeloproliferative disorders were treated with myeloablative immunosuppressive therapy followed by bone marrow transplantation (BMT). Four preparative regimens were used; three regimens consisted of combined total body irradiation (TBI) and chemotherapy and one of combination chemotherapy only. One patient received marrow from his identical twin brother, whereas the other 19 patients were grafted with marrow from histocompatible siblings. In 19 patients the abnormal clone was at least temporarily ablated, while in one patient the congenital myelodysplasia persisted. Eight patients are alive and well for + 108 to + 3,359 days posttransplantation. Nine patients died of transplant related complications (six of interstitial pneumonia, two of gastrointestinal bleeding, and one of fungal sepsis) and three patients died with persisting or recurring disease. One patient with a late recurrence has undergone a second successful bone marrow transplant procedure. Outcome of BMT was not related to French-American-British (FAB) type, marrow fibrosis, cytogenetic abnormalities, or preparation regimen. Marrow transplantation as a means of providing long-term disease-free survival and possible cure should be considered in patients if a suitable donor is available.

Original languageEnglish (US)
Pages (from-to)1822-1826
Number of pages5
JournalJournal of Clinical Oncology
Volume5
Issue number11
DOIs
StatePublished - Jan 1 1987

Fingerprint

Myelodysplastic Syndromes
Bone Marrow Transplantation
Bone Marrow
Siblings
Transplants
Myeloproliferative Disorders
Monozygotic Twins
Whole-Body Irradiation
Interstitial Lung Diseases
Immunosuppressive Agents
Combination Drug Therapy
Chromosome Aberrations
Disease-Free Survival
Sepsis
Fibrosis
Clone Cells
Transplantation
Tissue Donors
Hemorrhage
Recurrence

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

O'Donnell, M. R., Nademanee, A. P., Snyder, D. S., Schmidt, G. M., Parker, P. M., Bierman, P. J., ... Blume, K. G. (1987). Bone marrow transplantation for myelodysplastic and myeloproliferative syndromes. Journal of Clinical Oncology, 5(11), 1822-1826. https://doi.org/10.1200/JCO.1987.5.11.1822

Bone marrow transplantation for myelodysplastic and myeloproliferative syndromes. / O'Donnell, M. R.; Nademanee, A. P.; Snyder, D. S.; Schmidt, G. M.; Parker, P. M.; Bierman, Philip Jay; Fahey, J. L.; Stein, A. S.; Krance, R. A.; Stock, A. D.; Forman, S. J.; Blume, K. G.

In: Journal of Clinical Oncology, Vol. 5, No. 11, 01.01.1987, p. 1822-1826.

Research output: Contribution to journalArticle

O'Donnell, MR, Nademanee, AP, Snyder, DS, Schmidt, GM, Parker, PM, Bierman, PJ, Fahey, JL, Stein, AS, Krance, RA, Stock, AD, Forman, SJ & Blume, KG 1987, 'Bone marrow transplantation for myelodysplastic and myeloproliferative syndromes', Journal of Clinical Oncology, vol. 5, no. 11, pp. 1822-1826. https://doi.org/10.1200/JCO.1987.5.11.1822
O'Donnell, M. R. ; Nademanee, A. P. ; Snyder, D. S. ; Schmidt, G. M. ; Parker, P. M. ; Bierman, Philip Jay ; Fahey, J. L. ; Stein, A. S. ; Krance, R. A. ; Stock, A. D. ; Forman, S. J. ; Blume, K. G. / Bone marrow transplantation for myelodysplastic and myeloproliferative syndromes. In: Journal of Clinical Oncology. 1987 ; Vol. 5, No. 11. pp. 1822-1826.
@article{66b5e9bd14274ab3aa68f4d6b9f252aa,
title = "Bone marrow transplantation for myelodysplastic and myeloproliferative syndromes",
abstract = "Twenty patients (age range, 4 to 48 years; median age, 36 years) with de novo or drug-induced myelodysplastic syndromes or myeloproliferative disorders were treated with myeloablative immunosuppressive therapy followed by bone marrow transplantation (BMT). Four preparative regimens were used; three regimens consisted of combined total body irradiation (TBI) and chemotherapy and one of combination chemotherapy only. One patient received marrow from his identical twin brother, whereas the other 19 patients were grafted with marrow from histocompatible siblings. In 19 patients the abnormal clone was at least temporarily ablated, while in one patient the congenital myelodysplasia persisted. Eight patients are alive and well for + 108 to + 3,359 days posttransplantation. Nine patients died of transplant related complications (six of interstitial pneumonia, two of gastrointestinal bleeding, and one of fungal sepsis) and three patients died with persisting or recurring disease. One patient with a late recurrence has undergone a second successful bone marrow transplant procedure. Outcome of BMT was not related to French-American-British (FAB) type, marrow fibrosis, cytogenetic abnormalities, or preparation regimen. Marrow transplantation as a means of providing long-term disease-free survival and possible cure should be considered in patients if a suitable donor is available.",
author = "O'Donnell, {M. R.} and Nademanee, {A. P.} and Snyder, {D. S.} and Schmidt, {G. M.} and Parker, {P. M.} and Bierman, {Philip Jay} and Fahey, {J. L.} and Stein, {A. S.} and Krance, {R. A.} and Stock, {A. D.} and Forman, {S. J.} and Blume, {K. G.}",
year = "1987",
month = "1",
day = "1",
doi = "10.1200/JCO.1987.5.11.1822",
language = "English (US)",
volume = "5",
pages = "1822--1826",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "11",

}

TY - JOUR

T1 - Bone marrow transplantation for myelodysplastic and myeloproliferative syndromes

AU - O'Donnell, M. R.

AU - Nademanee, A. P.

AU - Snyder, D. S.

AU - Schmidt, G. M.

AU - Parker, P. M.

AU - Bierman, Philip Jay

AU - Fahey, J. L.

AU - Stein, A. S.

AU - Krance, R. A.

AU - Stock, A. D.

AU - Forman, S. J.

AU - Blume, K. G.

PY - 1987/1/1

Y1 - 1987/1/1

N2 - Twenty patients (age range, 4 to 48 years; median age, 36 years) with de novo or drug-induced myelodysplastic syndromes or myeloproliferative disorders were treated with myeloablative immunosuppressive therapy followed by bone marrow transplantation (BMT). Four preparative regimens were used; three regimens consisted of combined total body irradiation (TBI) and chemotherapy and one of combination chemotherapy only. One patient received marrow from his identical twin brother, whereas the other 19 patients were grafted with marrow from histocompatible siblings. In 19 patients the abnormal clone was at least temporarily ablated, while in one patient the congenital myelodysplasia persisted. Eight patients are alive and well for + 108 to + 3,359 days posttransplantation. Nine patients died of transplant related complications (six of interstitial pneumonia, two of gastrointestinal bleeding, and one of fungal sepsis) and three patients died with persisting or recurring disease. One patient with a late recurrence has undergone a second successful bone marrow transplant procedure. Outcome of BMT was not related to French-American-British (FAB) type, marrow fibrosis, cytogenetic abnormalities, or preparation regimen. Marrow transplantation as a means of providing long-term disease-free survival and possible cure should be considered in patients if a suitable donor is available.

AB - Twenty patients (age range, 4 to 48 years; median age, 36 years) with de novo or drug-induced myelodysplastic syndromes or myeloproliferative disorders were treated with myeloablative immunosuppressive therapy followed by bone marrow transplantation (BMT). Four preparative regimens were used; three regimens consisted of combined total body irradiation (TBI) and chemotherapy and one of combination chemotherapy only. One patient received marrow from his identical twin brother, whereas the other 19 patients were grafted with marrow from histocompatible siblings. In 19 patients the abnormal clone was at least temporarily ablated, while in one patient the congenital myelodysplasia persisted. Eight patients are alive and well for + 108 to + 3,359 days posttransplantation. Nine patients died of transplant related complications (six of interstitial pneumonia, two of gastrointestinal bleeding, and one of fungal sepsis) and three patients died with persisting or recurring disease. One patient with a late recurrence has undergone a second successful bone marrow transplant procedure. Outcome of BMT was not related to French-American-British (FAB) type, marrow fibrosis, cytogenetic abnormalities, or preparation regimen. Marrow transplantation as a means of providing long-term disease-free survival and possible cure should be considered in patients if a suitable donor is available.

UR - http://www.scopus.com/inward/record.url?scp=0023637016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023637016&partnerID=8YFLogxK

U2 - 10.1200/JCO.1987.5.11.1822

DO - 10.1200/JCO.1987.5.11.1822

M3 - Article

VL - 5

SP - 1822

EP - 1826

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 11

ER -